Your session is about to expire
← Back to Search
Belantamab mafodotin for Multiple Myeloma
Study Summary
This trial is for people who have received or are currently receiving treatment with belantamab mafodotin for multiple myeloma. The purpose is to get a better understanding of the corneal events seen in some patients receiving this treatment. A small piece of the superficial corneal epithelial tissue will be removed and studied. The trial will last for 4 months and involve 25 patients.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has Belantamab mafodotin been given the green light by the FDA?
"Belantamab mafodotin's safety is estimated to be a 3."
Are there any available slots left for people who want to participate in this research?
"Yes, this is an ongoing study that was first posted on May 13th, 2021. The primary purpose of the clinical trial is to collect data from 25 participants spread out over 6 sites."
Is this study being conducted at various locations around the city?
"There are six recruitment sites for this clinical trial, Chapel Hill, Westwood, New york and three other locations. If you are interested in participating in the trial, it would be best to select a site that is nearest to your location to minimize travel requirements."
What is the standard course of treatment for patients with Belantamab mafodotin?
"Belantamab mafodotin is an immunomodulatory drug that has been approved to treat patients with relapsed or refractory multiple myeloma, as well as those who have previously received treatment with a proteasome inhibitor."
How many people can sign up for this research project?
"Yes, this is an active clinical trial that was first posted on May 13th, 2021. The most recent update was on September 26th, 2022. They are looking for 25 patients total from 6 different locations."
Is this a novel clinical study?
"As of now, there are 33 on-going trials for Belantamab mafodotin in 221 cities and 34 countries. The first clinical study was sponsored by Karyopharm Therapeutics Inc in 2015. This initial Phase 1 & 2 trial had 518 participants and completed drug approval stages quickly. In the years since, only 2 more trials have been conducted."
Is this the first time Belantamab mafodotin has been trialed?
"Belantamab mafodotin was first studied in 2015 at Weill Cornell Medicine / NewYork Presbyterian Hospital. As of now, there are 2 completed trials and 33 active clinical trials. A notable amount of these studies taking place in Chapel Hill, North carolina."
What are the goals that this clinical trial is hoping to achieve?
"The primary objective of this clinical trial, as stated by the sponsor GlaxoSmithKline, is to evaluate the pathologic characteristics of participants after 4 months. Secondary outcomes being measured over the same time frame include changes in best corrected visual acuity (BCVA) score, corneal symptoms, and corneal epithelial lesions."
Share this study with friends
Copy Link
Messenger